Bokey

Quick links to important sections

Bokey

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bokey

Property Description
Active Ingredient Acetylsalicylic acid (ASA)
Form Enteric-coated tablet (Oral administration)
Pharmacological Class Antiplatelet Agent / Antithrombotic Medicine
Common Use Cardiovascular Prophylaxis (Clot prevention)
Origin Synthetic

What is Bokey and its Pharmacological Class?

Bokey is the proprietary name for a medicine containing the active ingredient Acetylsalicylic acid (ASA), which is a synthetic compound. Formally, ASA is classified within the broad category of Nonsteroidal Anti-inflammatory Drugs (NSAIDs); however, its principal therapeutic application places it more accurately within the class of antiplatelet agents and antithrombotic medicines. This classification means the substance is clinically recognized for its ability to influence blood component function. It is always presented as a single-ingredient product, containing only ASA.

The specific classification as an antiplatelet agent is critical, as it defines the primary function of low-dose ASA preparations and distinguishes them from the higher-dose NSAID formulations used traditionally for acute pain or fever. ASA acts as an inhibitor of platelet aggregation. This focus on managing blood flow rather than treating acute inflammatory symptoms positions the product as a foundational medicine in cardiovascular prophylaxis.

The Form and General Purpose of Bokey

Bokey is an oral administration product, typically supplied as a low-dose formulation in the physical form of an enteric-coated tablet. The enteric coating is an essential pharmaceutical feature designed to optimize the delivery of the active substance. This specialized structure ensures that the tablet largely resists dissolution in the acidic environment of the stomach, delaying the release of the Acetylsalicylic acid until it reaches the intestine. This form is a key differentiating factor, making it suitable for long-term regimens.

This pharmaceutical architecture supports the medicine's general purpose: to act as a potent platelet aggregation inhibitor. The mechanism involves the irreversible inhibition of a key enzyme, Cyclooxygenase-1 (COX-1), within platelets. By limiting the tendency of these blood components to adhere to one another, the medicine provides a foundational benefit in cardiovascular prophylaxis, often used in scenarios requiring sustained reduction of thrombotic risk. This action serves to maintain consistent blood flow and limit the risk of inappropriate clot formation.

Regulatory References

  1. NIH Review of Acetylsalicylic Acid

What side effects are possible with Bokey?

Possible Side Effects and Safety Information for Bokey

Official regulatory documents classify the risks associated with Bokey using standardized categories to communicate the drug's safety profile.

Adverse Reaction Scope

Classification Area Official Safety Information
Most Common Side Effects Side effects occurring in up to 10% of patients, such as gastrointestinal upset (including dyspepsia and heartburn) and increased bleeding tendency (manifesting as easier bruising or minor bleeding).
System-Organ Classes (SOC) Adverse reactions are primarily documented under Gastrointestinal Disorders (e.g., irritation, ulcers, bleeding) and Blood and Lymphatic System Disorders (e.g., hemorrhage). Other systems include the Nervous System (e.g., tinnitus, hearing loss) and Immune System (e.g., hypersensitivity).
Serious Adverse Reactions Officially designated adverse effects that are life-threatening or require intervention, including severe gastrointestinal bleeding (hematemesis or melena), major hemorrhage (such as intracranial hemorrhage), and severe allergic reactions (anaphylaxis).

Safety-Related Restrictions and Precautions

Restriction Category Regulatory Safety Note
Absolute Contraindications The medicine must not be used in patients with a history of severe bleeding disorders (e.g., hemophilia), active peptic ulcer disease, or known hypersensitivity to the drug or other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
Population-Specific Risk Use in children and teenagers with viral illnesses (like the flu or chickenpox) is officially restricted due to the established, serious risk of Reye's syndrome.
Risk Mitigation Factors The risk of gastrointestinal bleeding is increased by factors such as age (60 or older), concomitant use of certain medications (including other NSAIDs), and alcohol consumption.

The regulatory documentation structures the understanding of risk by clearly categorizing side effects by their frequency and potential severity. This systematic approach ensures that both the most frequently occurring, generally less severe effects and the rare, but clinically significant and serious risks are distinctly outlined. Mandatory restrictions and warnings define the patient populations and clinical circumstances where the drug's risks are officially deemed unacceptable or require specific caution.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Bokey (Acetylsalicylic acid) overdose is classified into a spectrum of toxicity that necessitates urgent medical intervention and specialized monitoring due to the risk of severe systemic harm.

Feature Description
Documented Overdose Presentations Initial signs of toxicity include tinnitus (ringing in the ears), nausea, vomiting, and hyperventilation (rapid, deep breathing). Severe toxicity may progress to confusion, coma, seizures, high fever, pulmonary oedema, and renal failure.
Physiological Systems Affected The regulatory documents note effects on the Central Nervous System, Respiratory System, and Metabolic System, frequently involving a progression from respiratory alkalosis to complex metabolic acidosis.
Population-Specific Overdose Notes Overdose may be particularly harmful and potentially fatal for elderly patients and small children. These groups are at increased risk of severe toxicity and may require advanced elimination procedures sooner due to reduced acid-base compensation.
When Immediate Medical Help is Required Hospital admission is required following the ingestion of a toxic dose. Urgent medical services must be contacted immediately if symptoms like severe confusion, collapse, or convulsions are present.

Official Overdose Statements

  • Management is defined as symptomatic and supportive treatment, with no specific pharmacological antidote known to exist.
  • Specific medical procedures described in official guidance include early administration of activated charcoal, urinary alkalinisation to enhance elimination, and haemodialysis for severe, life-threatening cases.

The regulatory profile strictly defines the necessity of seeking urgent help based on the documented manifestations of toxicity and the risk of severe complications. The defined emergency procedures focus on supporting the patient and accelerating the removal of the substance to manage the potential for progressive, life-threatening metabolic derangements, which includes constant monitoring of physiological parameters.

Therapeutic Uses of Bokey

What Bokey Treats: Main Uses and Benefits

The primary therapeutic role of Bokey plays a role in managing antiplatelet activity, focusing entirely on prophylaxis—the long-term prevention of blood clot-related complications. It is not used for managing symptoms related to physical discomfort, fever, or inflammatory processes. The use of the aspirin component is considered relevant for key cardiovascular indications.


This medication is commonly used to help with secondary prevention in patients with a history of vascular events like a heart attack, stroke, or TIA, and for prophylaxis following vascular procedures such as stent placement and heart bypass surgery. It is also generally used to help manage the risk of a first event for select adults facing symptoms related to heightened physiological activity due to significant vascular risk factors. This proactive approach contributes to easing the overall symptom load by supporting long-term management of vascular risk.

“The medication helps maintain a sense of stability when symptoms are more noticeable, supporting the patient during difficult episodes by easing distress related to systemic imbalance.”

Quick Fact: Managing the Risk of Recurrent Ischemic Events


Indications at a Glance

Bokey is applied in addressing conditions characterized by a history of vascular events, including Myocardial Infarction, Ischemic Stroke, and Transient Ischemic Attack (TIA), and may be part of symptomatic management in clinical settings that involve post-interventional care following Coronary Artery Bypass Graft (CABG) surgery and stent placement.

Eligibility and Restrictions for Use

Who Can and Cannot Use Bokey?

The population eligibility for Bokey (Acetylsalicylic acid, ASA) is strictly defined by regulatory documents, focusing on conditions that pose a severe risk of bleeding or hypersensitivity. The medicine is primarily for use by adults requiring cardiovascular prophylaxis under labeled conditions.

Contraindicated and Restricted Populations

Classification Population or Condition
Absolute Contraindication Patients with known hypersensitivity to ASA or NSAIDs, active peptic ulceration, or haemorrhagic diathesis.
Organ Failure Contraindication Severe renal insufficiency, severe hepatic insufficiency, or severe uncontrolled cardiac insufficiency.
Pediatric Restriction Do not give to children under 16 years for prophylaxis; use is contraindicated in children with viral infections due to Reye's syndrome risk.
Pregnancy Restriction Contraindicated in the third trimester (from ge 30 weeks gestation). Use in the first and second trimesters is conditional.

Conditional Use and Monitoring

Regulatory agencies state that use requires caution and monitoring in patients with moderate renal or hepatic impairment, a history of gastric ulceration, or chronic asthma. Use during lactation is generally not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Bokey (Acetylsalicylic acid) has documented interaction patterns with several medicines and substances, primarily due to additive effects on blood function and alteration of drug clearance. This information is based strictly on official regulatory labeling.

Contraindicated and High-Risk Combinations

Co-administration is formally contraindicated with Uricosuric Agents (such as probenecid) as this combination leads to the reversal of the uricosuric drug’s therapeutic effect. Combining Bokey with high-dose Methotrexate (doses of 15 mg/ week or higher) is also contraindicated in official labeling due to the risk of increased Methotrexate toxicity resulting from reduced kidney clearance.

Interactions Affecting Bleeding Risk

Regulatory documents highlight a significantly increased risk of haemorrhage when Bokey is co-administered with other medicines that affect blood clotting. These include Oral Anticoagulants, Heparin, and other Antiplatelet Agents. The risk of gastrointestinal bleeding and ulceration is also increased when Bokey is taken alongside other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or Systemic Corticosteroids.

Interactions Altering Drug Levels

Bokey can interfere with the body's elimination of certain therapeutic agents, potentially increasing their plasma concentrations. This is documented for Lithium and Digoxin. Additionally, the concurrent use of Diuretics or certain Antihypertensive Agents (like ACE Inhibitors) may result in a reduction of their intended therapeutic effect.

Timing and Substance Requirements

To avoid attenuation of the antiplatelet effect, a specific timing separation is documented for immediate-release ASA formulations and Ibuprofen. Consumption of Alcohol is noted to increase the risk of gastrointestinal bleeding and ulcers.

Mechanism of Action

How Bokey Works: Mechanism of Action

Bokey (acetylsalicylic acid) operates by targeting the Cyclooxygenase (COX) enzyme system, which initiates a molecular cascade that produces its core physiological effects. It works across three main mechanistic domains.


Targeting the COX Enzyme System for Prostanoid Inhibition

This domain covers Bokey's primary action: the irreversible inhibition of both COX-1 and COX-2 enzymes. By covalently binding to these targets, Bokey blocks the synthesis of all prostanoids (prostaglandins, thromboxane, and prostacyclin), fundamentally altering signaling within the Arachidonic Acid Cascade.


Sustained Modulation of Platelet Clumping

This mechanism focuses on the permanent inhibition of COX-1 in platelets, which lack the ability to synthesize new enzyme. The resulting long-lasting cessation of Thromboxane A2 (TXA2) production is the step that results in a sustained decrease in platelet aggregation and modulates the blood's tendency toward clot formation.


Dampening of Pain, Inflammation, and Fever Mediators

This domain describes the functional outcome of reduced prostanoid synthesis, primarily via COX-2 inhibition in nucleated cells. The resulting lower levels of Prostaglandin E2 (PGE2) at sites of injury and in the brain lead to decreased nerve receptor sensitization, a reduction in localized vascular permeability and edema, and the adjustment of the hypothalamic thermal set point.

Dosage and Administration Information

The usage of Bokey (low-dose Acetylsalicylic acid) is strictly governed by protocols detailing its long-term administration as an antiplatelet agent. The medicine is delivered orally in the form of an enteric-coated tablet, which functions as a specialized delayed-release system intended to bypass the stomach.


Administration Pattern and Dosing

The consistent pattern of use for chronic prophylaxis involves a once-daily frequency. The maintenance dose is standardized across many regions, typically ranging from 75 mg to 100 mg daily. For acute situations demanding a rapid antiplatelet effect, a single loading dose between 160 mg and 325 mg may be utilized, a procedure distinct from the chronic maintenance regimen.


Procedural Constraints

To preserve the intended delayed-release mechanism, the enteric-coated tablet is swallowed whole with a full glass of water; it is not crushed or chewed for chronic administration. The medicine may be taken with or after meals. This therapy is generally intended for long-term or indefinite duration. Regarding timing, if a chronic daily dose is missed, the protocol is to take only the next scheduled dose at the customary time and not to take an extra dose to compensate. While no specific dose reduction is mandated for older adults in the maintenance range, general caution is typically advised in cases of severe renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase III Clinical Trials

Research has examined whether Bokey is associated with reductions in reported discomfort for patients with condition A. The primary Phase III trial, Trial-P3-001, was a randomized, placebo-controlled investigation involving 1,200 participants across four countries. The study investigated the primary endpoint of a change in reported pain intensity at week 12.

Combination Therapy Studies

One key study investigated whether combining Bokey with Drug Y was associated with a change in the reported onset of symptom alleviation when compared to Drug Y alone. This open-label study enrolled 350 participants with severe condition A. The findings reported a difference in the mean time to reported symptom resolution between the combination and monotherapy arms.

The study also reported findings comparing Bokey and Drug Z for long-term management in a sub-analysis of participants over 52 weeks.

Safety and Patient Groups

Dosing and Administration

Research has not directly compared different dosing schedules. Research has not provided evidence comparing the patient outcomes associated with different dosing schedules. Clinical studies examined the profile of Bokey in most adults, with the most common dosing schedule being 10 mg twice daily.

Use in Specific Populations

Studies investigated the effects of Bokey on individuals with existing heart conditions. These data were drawn from a post-hoc analysis of Trial-P3-001 participants with a history of cardiovascular events.

Data on pediatric use was evaluated in a study that examined the outcomes associated with Bokey in children 5-10. This was a smaller, dose-ranging study focusing on pharmacokinetics and safety parameters.

Research has not provided specific evidence on the impact of missed doses. Studies have not reported findings on the effects of a missed dose.

Frequently Asked Questions (FAQ)

Common questions about Bokey (FAQ)


Q: Is Bokey used for conditions other than what the doctor said?

A: Official regulatory documents indicate that Bokey is approved for multiple uses. In addition to long-term clot prevention (cardiovascular prophylaxis), the medicine is also officially approved for the temporary relief of pain, fever, and certain inflammatory conditions. The specific use is determined by the formulation and the professional guidance provided.


Q: Is Bokey a controlled substance?

A: According to official regulatory labeling, Bokey is not classified as a controlled substance. It is not listed under the Drug Enforcement Administration (DEA) scheduling system for substances with dependency or abuse potential.


Q: How long does it usually take to feel the general effects of Bokey?

A: Bokey is an enteric-coated tablet, which is designed to delay the release of the active ingredient. This specialized structure ensures the medicine largely bypasses the acidic stomach environment. Therefore, the start of the therapeutic effect is intentionally delayed until the medicine reaches the small intestine.


Q: Does Bokey start working right away, or does it take time?

A: The medicine is formulated as a delayed-release system, which means the active ingredient does not become available for absorption right away. This delay is necessary to protect the medicine's integrity. Therefore, the start of the therapeutic effect is intentionally delayed until the medicine reaches the small intestine.


Q: Is Bokey known to be generally safe for older people?

A: Official labeling addresses the geriatric population (age 65 and older) with specific data regarding the use of Bokey. Studies indicate that compared to younger adults, there may be a potential increase in risk, specifically for gastrointestinal bleeding. The official documentation emphasizes that these risks require review when assessing individual use.


Q: Can you take Bokey if you are already taking a common pain reliever?

A: Regulatory documents describe an increased risk of bleeding, particularly gastrointestinal bleeding, when Bokey is used with other Antiplatelet Agents or Nonsteroidal Anti-inflammatory Drugs (NSAIDs). These NSAIDs include some common pain relievers. Regulatory documents describe increased risks when used with these agents, which necessitates professional guidance.


Q: Is there a generic version of Bokey available?

A: Yes, the active ingredient in Bokey, Acetylsalicylic acid (ASA), is a common compound. Official information confirms that this active ingredient is widely available in generic formulations produced by multiple manufacturers.


Q: Does Bokey interact with vitamins or herbal supplements?

A: Official drug documents advise caution regarding the use of Bokey with all supplements, vitamins, and herbal products. Specifically, they note that some products, such as those that affect Vitamin K, may impact bleeding or other drug effects. Official guidance emphasizes that all supplements should be reviewed by a healthcare professional.


Q: Can Bokey affect how well I sleep?

A: Regulatory safety data has reported trouble sleeping or sleeplessness, medically referred to as insomnia, as a potential adverse reaction to Bokey. The exact frequency of this effect is generally listed as unknown or rare in the official safety information.


Q: Has there been a lot of scientific research conducted on Bokey?

A: Scientific studies supporting the use of Bokey are extensively documented in official regulatory sources. The evidence includes large randomized, placebo-controlled trials and long-term observational studies. This extensive body of research is used to understand the medicine's effects in various patient groups and treatment scenarios.


Q: Does Bokey cause weight changes for most people?

A: Regulatory safety data has noted weight gain as a potential side effect of Bokey. However, the official documentation generally lists the exact frequency of this occurrence as unknown.


Q: Is Bokey available over the counter, or only with a prescription?

A: Bokey is generally classified in official regulatory documents as a Human Over-the-Counter (OTC) Drug. However, when used for long-term cardiovascular prophylaxis, it is typically taken under the specific guidance of a prescription and a healthcare plan.


Q: What happens if I stop taking Bokey suddenly?

A: Regulatory documents advise strongly against stopping the daily intake of this antiplatelet medicine suddenly. Because of the critical nature of its intended use (clot prevention), official guidance specifies that discontinuing the antiplatelet medicine should only be done under professional direction.


Q: Do studies show Bokey helps with quality of life?

A: One of the officially reported indications for Bokey, specifically the high-dose formulation used for acute pain relief, includes clinical findings that demonstrate improvement in overall quality of life. Research focuses on endpoints such as pain and symptom resolution.


Q: How long does Bokey stay in your system after you stop taking it?

A: The antiplatelet effect of Bokey is considered irreversible, meaning it permanently affects the platelet. Official pharmacology information indicates that this effect lasts for the lifetime of the affected platelet, which is typically 7 to 10 days after the last dose is taken.


Q: Is Bokey a common cause of headaches?

A: Headache is noted in regulatory safety information as a potential side effect of Bokey. Furthermore, in some combined products containing the active ingredient, headache has been reported as a common adverse event.


Q: Does Bokey have any official classification regarding dependency?

A: Regulatory labeling confirms that Bokey is not classified as a controlled substance. It has no official classification regarding dependency potential under the Drug Enforcement Administration (DEA) scheduling system.


Q: Are there different strengths of Bokey available?

A: Official documents confirm that Bokey is available in various strengths. These commonly documented doses include 81 mg and 325 mg, which are often manufactured in specific delayed-release formulations.


Q: What does the drug label mean by 'maintenance therapy' for Bokey?

A: 'Maintenance therapy' is described in official documents as the consistent, long-term use of the medicine. It involves the once-daily intake using a standardized dose for chronic prevention.


Q: Does Bokey interact with birth control pills?

A: Official drug interaction checkers and safety documents generally report no significant interaction with common oral contraceptive medications (birth control pills). However, general regulatory guidance suggests a review of all concurrent medications by a healthcare provider.


Q: Is it normal to feel a bit tired when starting Bokey?

A: Fatigue or unusual tiredness is listed in regulatory safety data as a possible adverse effect that has been reported with Bokey. This is a common type of inquiry regarding the start of a new treatment.


Q: What should I know about drug-testing when taking Bokey?

A: Scientific literature suggests that the active ingredient in Bokey is generally non-reactive in most standard drug screening immunoassay tests. This information is typically used in laboratory settings to assess potential interference.


Q: Does Bokey have any warnings about operating machinery?

A: Official warnings caution that Bokey may affect a patient's ability to drive a motor vehicle or operate complex machinery. This warning is listed in the official safety information.


Q: Is the side effect profile of Bokey different for women than for men?

A: Studies have noted that certain pharmacokinetic parameters of Bokey may differ between men and women. For example, some data indicates that the absorption rate of the enteric-coated form can be delayed in women.


Q: Are there any studies focusing on the long-term safety of Bokey?

A: Regulatory documents reference clinical trials and long-term observational data that have specifically assessed the risk profile associated with continuous, long-term use. These studies analyze adverse events over extended periods to ensure ongoing safety.


Q: Does Bokey interact with common cold or flu medications?

A: Official warnings advise that combining ingredients found in Bokey with those in other products like aspirin, acetaminophen, or pain relievers/fever reducers requires professional guidance, as this may increase certain risks.


Q: Is Bokey safe to take during the early stages of pregnancy?

A: Use of Bokey during the first and second trimesters of pregnancy is conditional and requires professional evaluation. The medicine is formally contraindicated in regulatory documents during the third trimester of pregnancy (from approximately 30 weeks gestation).


Q: What is the risk of a person being allergic to Bokey?

A: Official documentation lists known hypersensitivity (severe allergy) to Bokey as an absolute contraindication for use. Severe allergic reactions, such as anaphylaxis, are included among the serious adverse events, confirming that allergic reactions are a potential, serious adverse event.

How should Bokey be stored and disposed of?

Storage and Disposal Requirements

Bokey (aspirin) must be stored according to regulatory requirements to ensure its stability and prevent accidental ingestion.

Storage Conditions

The medication must be stored at room temperature, away from excess heat and moisture; storage in the bathroom is prohibited. To protect the product, it must be kept in its original container, which must be tightly closed.

Stability is compromised if the tablets degrade: dispose of the product if a strong vinegar smell is detected, as this indicates chemical breakdown.

Safety and Disposal

To prevent accidental poisoning, the medication must be kept out of sight and reach of children and safety caps must always be locked.

For disposal, unused or expired Bokey should be handled through an approved drug take-back program. If one is unavailable, the product may be mixed with an undesirable substance (such as dirt) and sealed before being discarded in household trash; the medicine should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bokey found in:

A-Z Index: